ArticleJournal of asthma and allergy2021
Health-Related Quality of Life and Productivity Among US Patients with Severe Asthma.
Article in Journal of asthma and allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03373045 (The CHRONICLE Study), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals With Severe Asthma in the United States
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Societal and personal financial burden of severe asthma and impact of biologic therapy: a 19-year nationwide cost analysis.BMJ open respiratory research · 2026Article
- Enhancing antioxidant capacity and reducing asthma risk: the impact of zinc and iron on molecular pathways.Clinical and experimental medicine · 2025Article
- Patient-centred outcomes in severe asthma: fatigue, sleep, physical activity and work.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Estimating the financial burden of asthma among young adults in Sweden.European clinical respiratory journal · 2025Article
- Quality of life and work functionality in severe asthma patients: the impact of biological therapies.Journal of occupational medicine and toxicology (London, England) · 2024Article
- Quality of Life Improvements with Biologic Initiation Among Subspecialist-Treated US Patients with Severe Asthma.Journal of asthma and allergy · 2024Article
- Influence of anti-interleukin (IL)-5/anti-IL-5 receptor-α treatment on work productivity in patients with severe eosinophilic asthma.ERJ open research · 2023Article
- A Charter to Fundamentally Change the Role of Oral Corticosteroids in the Management of Asthma.Advances in therapy · 2023Review
- Systemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness Group.The World Allergy Organization journal · 2022Review
- A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma.Advances in therapy · 2022Article
- Health-Related Quality of Life (HRQoL) of Residents with Persistent Lower Respiratory Symptoms or Asthma Following a Sulphur Stockpile Fire Incident.International journal of environmental research and public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHealth-related quality of life (HRQoL) and productivity of patients with confirmed severe asthma (SA) have not been well characterized in large, real-world populations. PURPOSE: To characterize SA impact on HRQoL, work productivity, and activity impairment in a large, real-world cohort in the United States (US).
methodsCHRONICLE is an observational study of specialist-treated adults (≥18 years) in the US with SA receiving biologics or maintenance systemic corticosteroids (mSCS), or those persistently uncontrolled by high-dosage inhaled corticosteroids with additional controllers (HD ICS+). At enrollment, patients completed the St. George's Respiratory Questionnaire (SGRQ) and Work Productivity and Activity Impairment (WPAI) questionnaire. Results were analyzed for those enrolled between February 2018 and February 2020.
resultsAmong patients who completed enrollment questionnaires (n = 1109), mean age was 54 years and most were women (70%). Among SGRQ respondents (n = 960), mean (SD) total score was 43 (23); 51% reported good/very good health. Among WPAI respondents (n = 1057; 566 employed), mean (SD) overall work impairment was 21% (25). Patients receiving biologics (vs mSCS, HD ICS+ only) had better SGRQ total scores (38 vs 59, 48) and lower work impairment (17% vs 34%, 27%). Patients with better SGRQ activity scores relative to symptom scores had better SGRQ impacts scores, total scores, and reported better overall health.
conclusionSA significantly affects HRQoL, work productivity, and activity. The SGRQ is a valuable research instrument for evaluating HRQoL in SA. Due to its association with HRQoL and overall health, activity impairment should be a focus when monitoring patients' disease control. STUDY REGISTRATION: ClinicalTrials.gov Identifier: NCT03373045.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.